COMMUNIQUÉS West-GlobeNewswire

CVRx Reports Second Quarter 2024 Financial and Operating Results
29/07/2024
MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
29/07/2024
FOSTER CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]
Rani Therapeutics to Participate in August Investor Conferences
29/07/2024
SAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and [...]
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
29/07/2024
Southlake, TX, July 29, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , an artificial intelligence (AI)-powered medical technology [...]
IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow
29/07/2024
Results to be announced at 8:00 a.m. Eastern time, conference call to begin at 8:30 a.m. Eastern time LAWRENCEVILLE, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in late [...]
Clearside Biomedical’s Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS® for Suprachoroidal Use in Uveitic Macular Edema Patients in China
29/07/2024
Primary and Secondary Endpoints Achieved with Favorable Tolerability and Safety Profile ALPHARETTA, Ga., July 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company [...]
Maravai LifeSciences Appoints Trey Martin to Board of Directors
29/07/2024
Maravai announces the appointment of CEO Trey Martin to its Board of Directors, highlighting his leadership, commitment to innovation, and industry experience SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Maravai [...]
T2 Biosystems Announces Second Quarter 2024 Financial Results
29/07/2024
Achieved record quarterly and first half sepsis test revenue, representing growth of 27% and 25% respectively compared to the prior year periods LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. ( [...]
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
29/07/2024
MENLO PARK, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, [...]
NurExone Announces Further Expansion of ExoPTEN Patent Coverage
29/07/2024
TORONTO and HAIFA, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company developing [...]
T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor
29/07/2024
LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a [...]
Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024
29/07/2024
SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
29/07/2024
Met primary endpoint demonstrating clinically meaningful and statistically significant complete response rate across both dose groups First large, randomized, placebo-controlled study to demonstrate success in CIndU [...]
Repligen Announces Agreement to Acquire Chromatography Innovator Tantti
29/07/2024
Proposed acquisition adds novel macroporous chromatography base bead technology for downstream bioprocess applications Accelerates expansion into new modality markets with a unique, scalable purification solution [...]
SAFE - Lancement d’un regroupement d’actions Safe
29/07/2024
Lancement d’un regroupement d’actions Safe 3.000 actions anciennes contre 1 action nouvelle Mise en œuvre des opérations de regroupement à compter du 14 août 2024 Premier jour de cotation des actions regroupées le 16 [...]
Fairway Consulting Group Recognized as a Top 40 Life Sciences Executive Search Firm by Hunt Scanlon
29/07/2024
NEW YORK, July 29, 2024 (GLOBE NEWSWIRE) -- Fairway Consulting Group (FCG) , a leading executive search firm focused on providing outstanding talent solutions for the pharmaceutical, biotechnology, diagnostic, and [...]
SAFE - COMPTE-RENDU DE L’ASSEMBLEE GENERALE EXTRAORDINAIRE DU 26 JUILLET 2024
29/07/2024
COMPTE-RENDU DE L’ASSEMBLEE GENERALE EXTRAORDINAIRE DU 26 JUILLET 2024 Fleurieux-sur-l’Arbresle - France - le 29 juillet 2024 à 18h15 . L’Assemblée Générale Extraordinaire des actionnaires de Safe (FR001400F1V2 – ALSAF [...]
SAFE - FIRST-HALF 2024 SALES
29/07/2024
FIRST-HALF 2024 SALES Fleurieux-sur-l’Arbresle - France - July 29, 2024, 6.00 p.m. The group Safe (FR001400F1V2 – ALSAF) announces consolidated sales for 1st half 2024. In k€ First-half 2024* First-half 2023 % change [...]
SAFE - CHIFFRE D’AFFAIRES DU 1ER SEMESTRE 2024
29/07/2024
CHIFFRE D’AFFAIRES DU 1 ER SEMESTRE 2024 Fleurieux-sur-l’Arbresle - France - le 29 juillet 2024 à 18h . Safe (FR001400F1V2 – ALSAF) annonce son chiffre d’affaires consolidé sur le 1 er semestre 2024. En k€ S1 2024* S1 [...]

Pages